Targeting IRAK4 in Chronic Lymphocytic Leukemia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- IRCCS San Raffaele
- Enrollment
- 50
- Primary Endpoint
- TLR signaling
Study Overview
Brief Summary
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Detailed Description
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC). Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 years
- •Diagnosis of CLL
- •Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria
- •- Participant is unable or unwilling to provide informed consent for participation in the study
Arms & Interventions
Study cohort
Collection of peripheral blood (up to 50 ml) for the analysis of the biological activity of IRAK4 Chimeric Degradation Activation Compound (CDAC) in purified CLL B cells, assessed by changes in proliferation, apoptosis, and signaling pathway activation following in vitro treatment.
Intervention: Peripheral blood sample collection (Procedure)
Outcomes
Primary Outcomes
TLR signaling
Time Frame: 12 months
In vitro inhibition of TLR signaling in CLL cells following exposure to IRAK4 CDAC, as assessed by modulation of downstream signaling molecules (e.g. phosphorylation status and/or degradation of key components of the TLR pathway).
Secondary Outcomes
No secondary outcomes reported
Investigators
Paolo Ghia
Prof
IRCCS San Raffaele